News & insights
Featured news
2 min read
Autoriteit Consument & Markt, the Dutch competition authority (ACM), indicated today that it would start a probe of Biogen’s conduct in relation to that firm’s multiple sclerosis medicine Tysabri® (active substance: natalizumab)(see, attached press release).
read
On 3 November 2026, Advocate General Szpunar (AG Szpunar) delivered his non-binding opinion (the Opinion) in Like Company v Google Ireland (C-250/25).
read
On 14 October 2026, the European Union (EU) and Mexico held the first meeting of their High-Level Dialogue on Health (the Dialogue).
For industry, three outcomes stand out: (i) planned cooperation between the European Medicines Agency (EMA) and Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS); (ii) a push for regulatory reliance; and (iii) joint work to diversify supply chains for critical medicines.
read
read
read
read
read
read
read
read
read